Samsung Receives FDA Clearance for AI Algorithms that Detect Lung Nodules in Chest X-rays
Retrieved on:
Thursday, October 28, 2021
Radiology, General Health, Health, FDA, Medical Devices, Hospitals, Technology, Other Technology, Massachusetts General Hospital, Diagnosis, Cade, Apple Inc. v. Samsung Electronics Co., Hospital, Steven Novella, Patient satisfaction, Workflow, Patient, FDA, Wangjing Nan (S) station, Food, Samsung, Severance Hospital, Samsung Medical Center, Marketing, Vuno, Samsung Digital Imaging, Multimedia, Food and Drug Administration, Artificial intelligence, Lung cancer, Solution, PACS, Digital radiography, Health, AI, Medical device, Medical imaging
NeuroLogica Corp. today announced it has received Food and Drug Administration (FDA) 510(k) clearance for its Auto Lung Nodule Detection (ALND) tool.
Key Points:
- NeuroLogica Corp. today announced it has received Food and Drug Administration (FDA) 510(k) clearance for its Auto Lung Nodule Detection (ALND) tool.
- View the full release here: https://www.businesswire.com/news/home/20211028005735/en/
Chest radiograph without Auto Lung Nodule Detection (ALND) and chest radiograph with lung nodule marked. - Aiding the reader's diagnosis by indicating the location of suspected lung nodules on chest X-ray images (posteroanterior chest radiographs).
- As part of our commitment to advancing diagnostic radiology using AI, Samsung is collaborating with Vuno, a leading developer of AI solutions in healthcare.